Replies to post #99721 on Biotech Values

[rkrw]

I don't think so.

As you can see Myeloma patients go through a lot of regimens. Onyx results don't change that.

[rkrw]

I would add the MM space is very crowded but it was already crowded before.

Abbott/Facet antibody looks very promising.
This Onxy compound looked good.
There's a next generation Revlimid that should be a lock.

Beyond that I'm not sure there's much to get overly excited about in MM and nothing in small cap biotech that I'm aware of. imo.